# Alberto J. Espay

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/alberto-j-espay/

## Facts

| Field | Value |
| --- | --- |
| Citations | 24,109 |
| Field | Parkinson's Disease Mechanisms and Treatments |
| h-index | 83 |
| i10-index | 316 |
| Last Known Institution | James Madison University |
| OpenAlex ID | https://openalex.org/A5041831296 |
| ORCID iD | https://orcid.org/0000-0002-3389-136X |
| Works | 732 |

## Researcher papers

- [Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study](https://scholariq.org/papers/continuous-intrajejunal-infusion-of-levodopa-carbidopa-intestinal-gel-for/)
- [Technology in Parkinson's disease: Challenges and opportunities](https://scholariq.org/papers/technology-in-parkinson-s-disease-challenges-and-opportunities/)
- [Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals](https://scholariq.org/papers/levodopa-dose-equivalency-in-parkinson-s-disease-updated-systematic-review-and/)
- [Long-term unsupervised mobility assessment in movement disorders](https://scholariq.org/papers/long-term-unsupervised-mobility-assessment-in-movement-disorders/)
- [A recurrent de novo mutation in KCNC1 causes progressive myoclonus epilepsy](https://scholariq.org/papers/a-recurrent-de-novo-mutation-in-kcnc1-causes-progressive-myoclonus-epilepsy/)
- [Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease](https://scholariq.org/papers/cognitive-performance-and-neuropsychiatric-symptoms-in-early-untreated-parkinson/)
- [Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression](https://scholariq.org/papers/effect-of-urate-elevating-inosine-on-early-parkinson-disease-progression/)
- [Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls](https://scholariq.org/papers/longitudinal-csf-biomarkers-in-patients-with-early-parkinson-disease-and-healthy/)
- [Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study](https://scholariq.org/papers/clinical-and-dopamine-transporter-imaging-characteristics-of-non-manifest-lrrk2/)

## Researcher topics

- [Parkinson's Disease Mechanisms and Treatments](https://scholariq.org/topics/parkinson-s-disease-mechanisms-and-treatments/)
- [Neurological disorders and treatments](https://scholariq.org/topics/neurological-disorders-and-treatments/)
- [Botulinum Toxin and Related Neurological Disorders](https://scholariq.org/topics/botulinum-toxin-and-related-neurological-disorders/)
- [Genetic Neurodegenerative Diseases](https://scholariq.org/topics/genetic-neurodegenerative-diseases/)
- [Parkinson's Disease and Spinal Disorders](https://scholariq.org/topics/parkinson-s-disease-and-spinal-disorders/)

## Researcher university

- [James Madison University](https://scholariq.org/institutions/james-madison-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.